Syros Pharmaceuticals (NASDAQ:SYRS) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Friday, BidAskClub reports.

A number of other analysts have also weighed in on the company. ValuEngine lowered Yirendai from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 26th. Wedbush reaffirmed an “outperform” rating on shares of Alphabet in a research report on Thursday, April 25th. Piper Jaffray Companies set a $44.00 price objective on First Merchants and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Zacks Investment Research lowered Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 9th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Syros Pharmaceuticals in a research report on Thursday, May 2nd. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Syros Pharmaceuticals has an average rating of “Buy” and a consensus target price of $15.66.

Shares of NASDAQ SYRS opened at $8.75 on Friday. The stock has a market capitalization of $371.26 million, a price-to-earnings ratio of -4.58 and a beta of 1.95. The company has a current ratio of 5.19, a quick ratio of 5.19 and a debt-to-equity ratio of 0.02. Syros Pharmaceuticals has a 52-week low of $5.17 and a 52-week high of $13.18. The firm has a 50 day moving average price of $7.01.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Wednesday, May 1st. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.08. Syros Pharmaceuticals had a negative return on equity of 74.28% and a negative net margin of 3,012.04%. The business had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.42 million. On average, analysts predict that Syros Pharmaceuticals will post -1.82 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of SYRS. BNP Paribas Arbitrage SA purchased a new position in Syros Pharmaceuticals in the first quarter valued at $48,000. Bank of America Corp DE increased its holdings in Syros Pharmaceuticals by 205.9% in the fourth quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock valued at $98,000 after buying an additional 11,711 shares during the last quarter. Rhumbline Advisers increased its holdings in Syros Pharmaceuticals by 51.4% in the fourth quarter. Rhumbline Advisers now owns 32,406 shares of the company’s stock valued at $181,000 after buying an additional 10,995 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its holdings in Syros Pharmaceuticals by 8.3% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,380 shares of the company’s stock valued at $369,000 after buying an additional 3,100 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Syros Pharmaceuticals by 8.9% in the fourth quarter. Bank of New York Mellon Corp now owns 84,537 shares of the company’s stock valued at $470,000 after buying an additional 6,883 shares during the last quarter. 56.16% of the stock is currently owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

See Also: Bear Market

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.